Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 2
1989 1
1991 1
1992 5
1993 1
1994 3
1995 2
1996 1
1997 1
1998 2
1999 2
2000 2
2001 1
2002 6
2003 4
2004 4
2005 4
2006 11
2007 4
2008 8
2009 10
2010 22
2011 26
2012 29
2013 33
2014 34
2015 24
2016 27
2017 37
2018 22
2019 32
2020 30
2021 0
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 22371464

358 results
Results by year
Filters applied: . Clear all
Page 1
What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
Thorat C, Xu K, Freeman SN, Bonnel RA, Joseph F, Phillips MI, Imoisili MA. Thorat C, et al. Pediatrics. 2012 Mar;129(3):516-21. doi: 10.1542/peds.2011-1798. Epub 2012 Feb 27. Pediatrics. 2012. PMID: 22371464
Therapies for inborn errors of metabolism: what has the orphan drug act delivered?
Talele SS, Xu K, Pariser AR, Braun MM, Farag-El-Massah S, Phillips MI, Thompson BH, Coté TR. Talele SS, et al. Pediatrics. 2010 Jul;126(1):101-6. doi: 10.1542/peds.2009-3246. Epub 2010 Jun 21. Pediatrics. 2010. PMID: 20566615
The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
Wellman-Labadie O, Zhou Y. Wellman-Labadie O, et al. Health Policy. 2010 May;95(2-3):216-28. doi: 10.1016/j.healthpol.2009.12.001. Epub 2009 Dec 29. Health Policy. 2010. PMID: 20036435
Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
Xu K, Coté TR. Xu K, et al. Brief Bioinform. 2011 Jul;12(4):341-5. doi: 10.1093/bib/bbr006. Epub 2011 Feb 26. Brief Bioinform. 2011. PMID: 21357612
Developing treatments for inborn errors: incentives available to the clinician.
Haffner ME. Haffner ME. Mol Genet Metab. 2004 Apr;81 Suppl 1:S63-6. doi: 10.1016/j.ymgme.2003.10.015. Mol Genet Metab. 2004. PMID: 15050976
Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years.
Braun MM, Farag-El-Massah S, Xu K, Coté TR. Braun MM, et al. Nat Rev Drug Discov. 2010 Jul;9(7):519-22. doi: 10.1038/nrd3160. Epub 2010 Jun 7. Nat Rev Drug Discov. 2010. PMID: 20531273 Review.
Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R, Spargo T, Seoane-Vazquez E. Rodriguez-Monguio R, et al. Orphanet J Rare Dis. 2017 Jan 5;12(1):1. doi: 10.1186/s13023-016-0551-7. Orphanet J Rare Dis. 2017. PMID: 28057032 Free PMC article.
Incentives for orphan drug research and development in the United States.
Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J. Seoane-Vazquez E, et al. Orphanet J Rare Dis. 2008 Dec 16;3:33. doi: 10.1186/1750-1172-3-33. Orphanet J Rare Dis. 2008. PMID: 19087348 Free PMC article.
The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
Burke KA, Freeman SN, Imoisili MA, Coté TR. Burke KA, et al. Clin Pharmacol Ther. 2010 Oct;88(4):449-53. doi: 10.1038/clpt.2010.193. Clin Pharmacol Ther. 2010. PMID: 20856241 Review.
Drug development for exceptionally rare metabolic diseases: challenging but not impossible.
Putzeist M, Mantel-Teeuwisse AK, Wied CC, Hoes AW, Leufkens HG, de Vrueh RL. Putzeist M, et al. Orphanet J Rare Dis. 2013 Nov 15;8:179. doi: 10.1186/1750-1172-8-179. Orphanet J Rare Dis. 2013. PMID: 24237580 Free PMC article.
358 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback